FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation

On November 6, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to vemurafenib for the treatment of adult patients with Erdheim‐Chester disease (ECD) with BRAFV600 mutation. ECD is a type of histiocytosis, a rare disorder characterized by an abnormal accumulation and behavi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncologist
Main Authors: Oneal, Patricia A., Kwitkowski, Virginia, Luo, Lola, Shen, Yuan Li, Subramaniam, Sriram, Shord, Stacy, Goldberg, Kirsten B., McKee, Amy E., Kaminskas, Edvardas, Farrell, Ann, Pazdur, Richard
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Inc. 2018
Fag:
Regulatory Issues: FDA
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6292556/
https://ncbi.nlm.nih.gov/pubmed/30120160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0295
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker